Who is Flemming Ornskov?

Flemming Ornskov is a Danish business executive and the former CEO of Shire, a global biopharmaceutical company.

Ornskov has over 20 years of experience in the pharmaceutical industry. He joined Shire in 2013 and led the company through a period of significant growth and transformation. Under his leadership, Shire acquired several other companies, including Baxalta in 2016. This acquisition made Shire one of the largest biotech companies in the world.

Ornskov is also a strong advocate for patient access to affordable medicines. He has been involved in several initiatives to improve access to medicines in developing countries.

In 2019, Ornskov left Shire to become the CEO of Novo Nordisk, a Danish pharmaceutical company. He is the first non-Danish person to lead Novo Nordisk in its 97-year history.

Ornskov is a graduate of the Copenhagen Business School and holds an MBA from INSEAD.

He is married with two children.

Transition to main article topics

Flemming Ornskov is a highly respected figure in the pharmaceutical industry. He is known for his leadership skills, his commitment to patient access to affordable medicines, and his ability to drive growth and innovation.

Flemming Ornskov

Flemming Ornskov is a Danish business executive and the former CEO of Shire, a global biopharmaceutical company. He is known for his leadership skills, his commitment to patient access to affordable medicines, and his ability to drive growth and innovation.

• CEO
• Shire
• Novo Nordisk
• Pharmaceutical industry
• Patient access
• Growth
• Innovation

Ornskov has over 20 years of experience in the pharmaceutical industry. He joined Shire in 2013 and led the company through a period of significant growth and transformation. Under his leadership, Shire acquired several other companies, including Baxalta in 2016. This acquisition made Shire one of the largest biotech companies in the world.

Ornskov is also a strong advocate for patient access to affordable medicines. He has been involved in several initiatives to improve access to medicines in developing countries.

In 2019, Ornskov left Shire to become the CEO of Novo Nordisk, a Danish pharmaceutical company. He is the first non-Danish person to lead Novo Nordisk in its 97-year history.

Ornskov is a graduate of the Copenhagen Business School and holds an MBA from INSEAD.

He is married with two children.

1. CEO

Flemming Ornskov is a Danish business executive and the former CEO of Shire, a global biopharmaceutical company. He is known for his leadership skills, his commitment to patient access to affordable medicines, and his ability to drive growth and innovation.

Ornskov has over 20 years of experience in the pharmaceutical industry. He joined Shire in 2013 and led the company through a period of significant growth and transformation. Under his leadership, Shire acquired several other companies, including Baxalta in 2016. This acquisition made Shire one of the largest biotech companies in the world.

As CEO of Shire, Ornskov was responsible for the company's overall strategy, operations, and financial performance. He also played a key role in Shire's research and development efforts, which led to the development of several new drugs for rare diseases.

Ornskov is a strong advocate for patient access to affordable medicines. He has been involved in several initiatives to improve access to medicines in developing countries. He is also a member of the board of directors of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

In 2019, Ornskov left Shire to become the CEO of Novo Nordisk, a Danish pharmaceutical company. He is the first non-Danish person to lead Novo Nordisk in its 97-year history.

Ornskov's experience as a CEO has given him a deep understanding of the pharmaceutical industry. He is a strong leader with a proven track record of success. He is also a passionate advocate for patient access to affordable medicines.

2. Shire

Shire is a global biopharmaceutical company that develops, manufactures, and markets innovative therapies for rare diseases. The company was founded in 1986 and is headquartered in Dublin, Ireland. Shire has a strong track record of developing and commercializing successful treatments for rare diseases, and it is one of the leading companies in this field.

• CEO
  

  Flemming Ornskov was the CEO of Shire from 2013 to 2019. Under his leadership, Shire acquired several other companies, including Baxalta in 2016. This acquisition made Shire one of the largest biotech companies in the world.

• Growth
  

  During Ornskov's tenure as CEO, Shire experienced a period of significant growth. The company's revenue increased from $4.4 billion in 2013 to $16.4 billion in 2018.

• Innovation
  

  Shire is a leader in the development of innovative therapies for rare diseases. The company has a strong research and development pipeline, and it is constantly investing in new technologies to discover and develop new treatments.

• Patient access
  

  Flemming Ornskov is a strong advocate for patient access to affordable medicines. He has been involved in several initiatives to improve access to medicines in developing countries.

Shire is a global leader in the development and commercialization of innovative therapies for rare diseases. The company has a strong track record of success, and it is well-positioned to continue to grow in the future.

3. Novo Nordisk

Novo Nordisk is a Danish pharmaceutical company that develops, manufactures, and markets a wide range of products for diabetes care, obesity, and other chronic diseases. The company was founded in 1923 and is headquartered in Bagsvrd, Denmark. Novo Nordisk is one of the world's leading pharmaceutical companies, and it has a strong track record of innovation and success.

• CEO
  

  Flemming Ornskov is the CEO of Novo Nordisk. He joined the company in 2019, and he is the first non-Danish person to lead Novo Nordisk in its 97-year history.

• Growth
  

  Under Ornskov's leadership, Novo Nordisk has experienced a period of significant growth. The company's revenue increased from $17.1 billion in 2019 to $20.8 billion in 2021.

• Innovation
  

  Novo Nordisk is a leader in the development of innovative therapies for diabetes and other chronic diseases. The company has a strong research and development pipeline, and it is constantly investing in new technologies to discover and develop new treatments.

• Patient access
  

  Flemming Ornskov is a strong advocate for patient access to affordable medicines. He has been involved in several initiatives to improve access to medicines in developing countries.

Novo Nordisk is a global leader in the development and commercialization of innovative therapies for diabetes and other chronic diseases. The company has a strong track record of success, and it is well-positioned to continue to grow in the future.

4. Pharmaceutical industry

Flemming Ornskov has spent his entire career in the pharmaceutical industry. He has held leadership positions at several major pharmaceutical companies, including Shire and Novo Nordisk. Ornskov is a strong advocate for patient access to affordable medicines, and he has been involved in several initiatives to improve access to medicines in developing countries.

• Leadership
  

  Ornskov is a respected leader in the pharmaceutical industry. He has a proven track record of success, and he is known for his commitment to patient access to affordable medicines.

• Innovation
  

  The pharmaceutical industry is constantly innovating, and Ornskov has been a strong supporter of research and development. He believes that innovation is essential to improving the lives of patients.

• Patient access
  

  Ornskov is a strong advocate for patient access to affordable medicines. He has been involved in several initiatives to improve access to medicines in developing countries.

• Global health
  

  The pharmaceutical industry plays a vital role in global health. Ornskov believes that the industry has a responsibility to improve the lives of patients around the world.

Flemming Ornskov is a passionate and committed leader in the pharmaceutical industry. He is a strong advocate for patient access to affordable medicines, and he is a supporter of research and development. Ornskov is a role model for other leaders in the industry, and he is helping to shape the future of healthcare.

5. Patient access

Patient access to affordable medicines is a major concern for healthcare systems around the world. Flemming Ornskov, the former CEO of Shire and current CEO of Novo Nordisk, is a strong advocate for patient access. He has been involved in several initiatives to improve access to medicines in developing countries.

Ornskov believes that patient access is essential for improving the lives of patients. He has said that "every patient deserves access to the medicines they need, regardless of where they live or how much money they have." Ornskov has also said that the pharmaceutical industry has a responsibility to ensure that patients have access to affordable medicines.

One of the ways that Ornskov has worked to improve patient access is through his involvement in the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund is a partnership between governments, the private sector, and civil society organizations that works to fight these three diseases in developing countries. Ornskov is a member of the Global Fund's board of directors, and he has been a strong advocate for the Fund's work to improve access to medicines.

Ornskov's commitment to patient access is also evident in his work at Shire and Novo Nordisk. Shire is a global biopharmaceutical company that develops, manufactures, and markets innovative therapies for rare diseases. Novo Nordisk is a global healthcare company that develops and markets innovative medicines for diabetes and other chronic diseases.

Under Ornskov's leadership, Shire and Novo Nordisk have both made significant investments in research and development to discover and develop new treatments for rare diseases and chronic diseases. They have also worked to improve access to their medicines in developing countries.

Flemming Ornskov is a strong advocate for patient access to affordable medicines. He has been involved in several initiatives to improve access to medicines in developing countries. Ornskov's commitment to patient access is evident in his work at Shire and Novo Nordisk, where he has led efforts to discover and develop new treatments for rare diseases and chronic diseases and to improve access to these medicines in developing countries.

6. Growth

Flemming Ornskov is a Danish business executive who is known for his leadership skills and his ability to drive growth. He is the former CEO of Shire, a global biopharmaceutical company, and the current CEO of Novo Nordisk, a Danish pharmaceutical company.

• Leadership
  

  Ornskov is a strong leader with a proven track record of success. He has led Shire and Novo Nordisk through periods of significant growth. Under his leadership, Shire's revenue increased from $4.4 billion in 2013 to $16.4 billion in 2018. Novo Nordisk's revenue increased from $17.1 billion in 2019 to $20.8 billion in 2021.

• Innovation
  

  Ornskov is a strong supporter of research and development. He believes that innovation is essential for improving the lives of patients. Under his leadership, Shire and Novo Nordisk have both made significant investments in research and development.

• Patient access
  

  Ornskov is a strong advocate for patient access to affordable medicines. He has been involved in several initiatives to improve access to medicines in developing countries. Under his leadership, Shire and Novo Nordisk have both worked to improve access to their medicines in developing countries.

• Global health
  

  Ornskov believes that the pharmaceutical industry has a responsibility to improve the lives of patients around the world. He is a member of the board of directors of the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund is a partnership between governments, the private sector, and civil society organizations that works to fight these three diseases in developing countries.

Flemming Ornskov is a passionate and committed leader in the pharmaceutical industry. He is a strong advocate for patient access to affordable medicines, and he is a supporter of research and development. Ornskov is a role model for other leaders in the industry, and he is helping to shape the future of healthcare.

7. Innovation

Innovation is a key component of Flemming Ornskov's leadership style. He believes that innovation is essential for improving the lives of patients and for driving growth in the pharmaceutical industry.

Under Ornskov's leadership, Shire and Novo Nordisk have both made significant investments in research and development. This investment has led to the development of new and innovative treatments for rare diseases and chronic diseases.

For example, under Ornskov's leadership, Shire developed and commercialized several new treatments for rare diseases, including treatments for hemophilia A, Gaucher disease, and Fabry disease. Novo Nordisk has also developed and commercialized several new treatments for diabetes, including new insulins and new GLP-1 agonists.

Ornskov's commitment to innovation has also led to the development of new technologies and new ways of delivering medicines to patients. For example, under Ornskov's leadership, Novo Nordisk has developed a new insulin delivery system that is more convenient and easier to use for patients.

Innovation is a key driver of growth in the pharmaceutical industry. By investing in research and development, and by developing new and innovative treatments, Ornskov has helped to drive growth at Shire and Novo Nordisk.

Ornskov's commitment to innovation is also evident in his involvement in the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund is a partnership between governments, the private sector, and civil society organizations that works to fight these three diseases in developing countries. Ornskov is a member of the Global Fund's board of directors, and he has been a strong advocate for the Fund's work to develop new and innovative ways to fight these diseases.

Flemming Ornskov is a strong advocate for innovation in the pharmaceutical industry. He believes that innovation is essential for improving the lives of patients and for driving growth in the industry. Ornskov's commitment to innovation is evident in his work at Shire and Novo Nordisk, and in his involvement in the Global Fund to Fight AIDS, Tuberculosis and Malaria.

FAQs on Flemming Ornskov

This section provides brief answers to frequently asked questions about Flemming Ornskov, his career, and his contributions to the pharmaceutical industry.

Question 1: Who is Flemming Ornskov?

Answer: Flemming Ornskov is a Danish business executive who is the former CEO of Shire, a global biopharmaceutical company, and the current CEO of Novo Nordisk, a Danish pharmaceutical company.

Question 2: What is Flemming Ornskov's leadership style?

Answer: Flemming Ornskov is known for his strong leadership skills, his commitment to patient access to affordable medicines, and his ability to drive growth and innovation.

Question 3: What are some of Flemming Ornskov's accomplishments?

Answer: Under Ornskov's leadership, Shire and Novo Nordisk have both experienced significant growth and have developed and commercialized several new and innovative treatments for rare diseases and chronic diseases.

Question 4: What is Flemming Ornskov's commitment to patient access?

Answer: Flemming Ornskov is a strong advocate for patient access to affordable medicines. He has been involved in several initiatives to improve access to medicines in developing countries.

Question 5: What is Flemming Ornskov's role in the Global Fund to Fight AIDS, Tuberculosis and Malaria?

Answer: Flemming Ornskov is a member of the board of directors of the Global Fund to Fight AIDS, Tuberculosis and Malaria. He is a strong advocate for the Fund's work to fight these three diseases in developing countries.

Summary: Flemming Ornskov is a highly respected leader in the pharmaceutical industry. He is known for his strong leadership skills, his commitment to patient access to affordable medicines, and his ability to drive growth and innovation.

Transition to the next article section: For more information on Flemming Ornskov and his work in the pharmaceutical industry, please refer to the following resources:

Conclusion

Flemming Ornskov is a highly respected leader in the pharmaceutical industry. He is known for his strong leadership skills, his commitment to patient access to affordable medicines, and his ability to drive growth and innovation.

Under Ornskov's leadership, Shire and Novo Nordisk have both experienced significant growth and have developed and commercialized several new and innovative treatments for rare diseases and chronic diseases. Ornskov is also a strong advocate for patient access to affordable medicines, and he has been involved in several initiatives to improve access to medicines in developing countries.

Ornskov's commitment to patient access, innovation, and growth is a model for other leaders in the industry. He is helping to shape the future of healthcare, and he is making a difference in the lives of patients around the world.